Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.62 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.62 |
| ▸ | EGFR | P00533 | 6/20 | 0.60 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.57 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.57 |
| ▸ | TNF | P01375 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6268307 | 1.00 | GALR3 (0.62) | GALR3NR2F2EGFRTTBK1TTBK2 | |
| SCHEMBL28081345 | 0.81 | PIK3CD (0.53) | EGFRTTBK1TTBK2 | |
| SCHEMBL28081346 | 0.81 | PIK3CD (0.53) | EGFRTTBK1TTBK2 | |
| SCHEMBL1815838 | 0.81 | HPGDS (0.55) | TTBK1TTBK2 | |
| SCHEMBL28502338 | 0.80 | TTBK1 (0.57) | TTBK1TTBK2 | |
| SCHEMBL4809846 | 0.78 | GALR3 (0.61) | GALR3NR2F2EGFRTNFRAB9A | |
| SCHEMBL2197866 | 0.78 | TTBK1 (0.52) | EGFRTTBK1TTBK2 | |
| SCHEMBL17181108 | 0.77 | GALR3 (1.00) | GALR3NR2F2EGFRTNFRAB9A | |
| SCHEMBL5312802 | 0.77 | GALR3 (1.00) | GALR3NR2F2EGFRTNFRAB9A | |
| SCHEMBL5019518 | 0.77 | LMNA (0.64) | GALR3NR2F2EGFRTNFRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368147-A1 | CYCLIN K DEGRADER | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4382519-A1 | CYCLIN K DEGRADATION AGENT | Adlai Nortye Biopharma Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| CN-118141921-A | Use of CAMK2 inhibitors for the preparation of a medicament for reducing resistance to EGFR-driven cancers | 四川大学 | 2024-06-07 | — | — | CN | disclosed |
| CN-111918863-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| CN-110036033-B | Chimeric phagocytic receptor molecules | 森罗治疗公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117098776-A | Use of anti-TGF-beta antibodies and other therapeutic agents for the treatment of proliferative diseases | 诺华股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116390936-A | Chimeric TIM receptors and uses thereof | 森罗治疗公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116134027-A | Heteroaryl-substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-116096426-A | CCR7 antibody drug conjugates for the treatment of cancer | 诺华股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116096862-A | ZBTB32 inhibitors and uses thereof | 诺华股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-11634497-B2 | Anti-CCR7 antibody drug conjugates | NOVARTIS AG (CH) | 2023-04-25 | — | — | US | disclosed |
| CN-115052662-A | Use of anti-TGF-beta antibodies and checkpoint inhibitors for treating proliferative diseases | 诺华股份有限公司 | 2022-09-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368147-A1 | CYCLIN K DEGRADER | CCNK, CCNI, CDK1 | GALR3 4733/4885NR2F2 2534/4885EGFR 569/4885 |
| US-11634497-B2 | Anti-CCR7 antibody drug conjugates | CCR7, CXCR3, CXCR4 | GALR3 409/4885NR2F2 578/4885EGFR 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.